MedTrace Logo

STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

NCT02943590 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"

Conditions

Interventions

DRUG

Placebo

A pill taken once a day

DRUG

Atorvastatin

A pill taken once a day

Sponsors & Collaborators

Principal Investigators

  • Tomas G Neilan, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-13
Primary Completion
2022-09-16
Completion
2023-10-11

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943590 on ClinicalTrials.gov